Samsung Biologics plans to expand its presence with the construction of a new manufacturing facility located at Incheon.
The new facility is designed for drug product capacity to meet the growing demand of drugs and also to ensure flexible production capabilities.
The expansion includes addition of small-scale cartridge and syringe filling to Drug Product (DP) offerings and by raising the total lyophilisation capacity by 246 per cent of the existing capacity.
The project investments include building of a flexible filling line and two additional lyophiliser units with 41.2 m2 chambers.
The new project with a flexible filling line is expected to start GMP operations in the second half of 2021. In addition, expanded lyophilisation line will become operational in the first half of 2022.